Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex Therapy (AZTEK EXT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00692874
Recruitment Status : Completed
First Posted : June 6, 2008
Last Update Posted : December 10, 2010
Information provided by:

Brief Summary:
This is an open label, non-interventional quality of life analysis for Zoladex treated prostate cancer patients by investigator's questionnaire

Condition or disease
Prostate Cancer

Study Type : Observational
Actual Enrollment : 1646 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Quality of Life Analysis of Prostate Cancer Patient's Therapy
Study Start Date : June 2008
Actual Primary Completion Date : July 2010
Actual Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Primary Outcome Measures :
  1. Elements of a general and three disease-specific investigator questionnaire [ Time Frame: Quarterly (plus or minus 3 days ) ]

Secondary Outcome Measures :
  1. Investigator Assessment Report [ Time Frame: Yearly (plus or minus 1 week ) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Early or locally-advanced prostate cancer patients on androgen deprivation therapy

Inclusion Criteria:

  • Provision of informed consent
  • Early or locally-advanced prostate cancer patients on androgen deprivation therapy
  • Investigators are requested to recruit patients only with at least 1 month prior Zoladex treatment.

Exclusion Criteria:

  • Allergy to substance of medication
  • Prostate cancer patients with advanced disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00692874

Research Site
Baja, Hungary
Research Site
Bekescsaba, Hungary
Research Site
Bekes, Hungary
Research Site
Budapest, Hungary
Research Site
Cegled, Hungary
Research Site
Dunaujvaros, Hungary
Research Site
Erd, Hungary
Research Site
Gyor, Hungary
Research Site
Gyula, Hungary
Research Site
Kiskunhalas, Hungary
Research Site
Nagykoros, Hungary
Research Site
Nyiregyhaza, Hungary
Research Site
Pecs, Hungary
Research Site
Sopron, Hungary
Research Site
Szeged, Hungary
Research Site
Szekesfehervar, Hungary
Research Site
Szentendre, Hungary
Research Site
Tatabanya, Hungary
Research Site
Vac, Hungary
Research Site
Zalaegerszeg, Hungary
Sponsors and Collaborators
Principal Investigator: Péter Tenke, M.D. "Jahn Ferenc" City Hospital Budapest
Study Director: Csaba Csongvai AstraZeneca Hungary
Study Chair: Éva Gulyás AstraZeneca Hungary

Responsible Party: Francisco Sapunar Medical Science Director, AstraZeneca Identifier: NCT00692874     History of Changes
Other Study ID Numbers: NIS-OHU-ZOL-2007/1
First Posted: June 6, 2008    Key Record Dates
Last Update Posted: December 10, 2010
Last Verified: December 2010

Keywords provided by AstraZeneca:
Quality of Life

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases